secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2024-07-15T23:59:59+00:00
Accession:  0001193125-24-179108
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec reports durable swallowing improvements at 180 days for first BB-301 subject in Phase 1b/2a
--------------------------------------------------------------------------------

- Post-dose Total Pharyngeal Residue meaningfully reduced at 180 days vs pre-dose average for Subject 1.
- For 3 of 4 food types, TPR at 180 days lower than any point in 9-month natural history study; fourth similar to lowest.
- SSQ Total Score at 180 days lower than any point in 9-month pre-dose period, indicating improved swallowing.
- No SAEs observed; transient Grade 2 GERD previously reported.
- Second subject dosed Feb 2024; third expected Q3 2024; additional interim data in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524179108/0001193125-24-179108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524179108/d819205d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-179108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer